Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 21,219 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $152,352.42. Following the sale, the insider now directly owns 3,499,099 shares of the company's stock, valued at approximately $25,123,530.82. This trade represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ocular Therapeutix Trading Down 1.6%

Shares of NASDAQ OCUL traded down $0.13 during mid-day trading on Friday, hitting $8.01. The stock had a trading volume of 2,177,691 shares, compared to its average volume of 1,411,178. The business has a 50 day moving average price of $7.36 and a two-hundred day moving average price of $7.95. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The firm has a market cap of $1.28 billion, a P/E ratio of -6.07 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million for the quarter, compared to analysts' expectations of $16.89 million. On average, equities analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Thursday. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Needham & Company LLC reduced their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Royal Bank of Canada started coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price on the stock. Finally, William Blair initiated coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $16.25.

Institutional Trading of Ocular Therapeutix

Several large investors have recently modified their holdings of OCUL. Raymond James Financial Inc. bought a new position in Ocular Therapeutix during the 4th quarter valued at approximately $1,722,000. Charles Schwab Investment Management Inc. increased its stake in shares of Ocular Therapeutix by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock valued at $9,663,000 after buying an additional 21,025 shares during the period. Barclays PLC raised its holdings in shares of Ocular Therapeutix by 37.1% during the third quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after acquiring an additional 138,441 shares in the last quarter. ProShare Advisors LLC lifted its stake in Ocular Therapeutix by 32.8% in the fourth quarter. ProShare Advisors LLC now owns 51,270 shares of the biopharmaceutical company's stock worth $438,000 after acquiring an additional 12,669 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 8,446 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.